LongeVC

Constructive Bio is a biotechnology company that rewrites genomes to turn living cells into biofactories for sustainable materials and therapeutics. By controlling the genetic sequence, it enables the biosynthesis of enzymes, pharmaceuticals, and biomaterials while exploring chemical space beyond natural biology. The approach includes developing virus-resistant organisms and supporting next-generation bioprocesses and biopharmaceuticals.

SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.

Proton Intelligence, founded in 2020 and headquartered in Vancouver, Canada, specializes in biomarker monitoring to manage chronic diseases and enhance patient outcomes. The company focuses on continuous potassium monitoring, particularly for patients suffering from hyperkalemia associated with chronic kidney disease and other co-morbidities. Proton Intelligence's innovative platform provides accurate and real-time potassium measurements through interstitial fluid analysis, which correlates closely with blood levels. This capability is critical for enabling timely and informed decision-making regarding patient care, allowing clinicians and patients to effectively manage medications, dietary choices, and treatment options. By prioritizing precise monitoring, Proton Intelligence aims to significantly improve the health and lives of individuals affected by hyperkalemia.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Catena Biosciences is a biotechnology firm focused on advancing protein conjugation technology to address autoimmune disorders and other medical challenges. The company specializes in a method that facilitates the rapid and selective attachment of proteins, utilizing natural amino acids such as tyrosine and cysteine. This innovative approach allows researchers to develop novel therapeutics across various fields, including autoimmune disorders, oncology, and vaccine development. By streamlining the process of building biologic structures, Catena Biosciences aims to enhance medical research and contribute to the creation of effective treatments.

Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing innovative therapies that target senescent cells implicated in age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of therapeutic candidates. These candidates are designed to selectively address senescent cells, as well as pro-inflammatory and pro-fibrotic cell populations that contribute to various chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises industry experts with significant experience in drug development and commercialization across both large pharmaceutical companies and biotech firms.

Ani Biome is a longevity biotech startup that has the mission of optimizing and enhancing one's mind

Unnatural Products Inc. is a biotechnology company based in Santa Cruz, California, focused on drug discovery through innovative technology. Founded in 2016, the company specializes in designing and developing a platform that utilizes artificial intelligence and computational biology techniques to create macrocyclic peptides. These peptides target intracellular protein interactions, addressing drug targets that are typically considered undruggable. By harnessing machine learning to optimize chemical synthesis, Unnatural Products aims to accelerate the drug discovery process, offering potential therapeutic strategies for a wide range of medical conditions. Through its unique approach, the company seeks to pioneer new treatments where traditional methods have fallen short.

Interface Biosciences is a platform therapeutics company that focuses on leveraging the human microbiome to develop innovative treatments for inflammatory diseases. The company specializes in creating therapeutic-microbial metabolite drugs that explore the interactions between the microbiome and the immune system. By addressing the causal mechanisms of microbe-mediated immune cell activation and repression, Interface Biosciences aims to develop multi-functional molecules that can target various biological pathways in humans or microbes. Its pipeline is designed to address conditions such as eczema, inflammatory bowel disease (IBD), and certain oncology targets, including premalignant lesions. This approach enables healthcare professionals to efficiently treat chronic inflammatory diseases.

Haut.AI is a pioneering beauty technology company that specializes in artificial intelligence-powered software for skin analysis and personalized skincare solutions. Its flagship product, Skin Atlas, enables detailed online skin assessments by automating the collection of skin data and calculating essential health and beauty metrics. The platform emphasizes data privacy through features such as image anonymization, allowing customers, brands, and retailers to access tailored skincare experiences without compromising personal information. By facilitating interactive product recommendations on e-commerce platforms, Haut.AI empowers skincare brands to enhance their customer engagement and improve product offerings based on individual skin needs.

AOA, based in Boston, New York, and London, is a female-led company focused on developing innovative cancer diagnostics specifically for women's health. The company is dedicated to creating the first accurate early-stage liquid biopsy test for ovarian cancer, which aims to enhance clinical practices, reduce patient mortality, and offer cost savings for healthcare payers. Utilizing an artificial intelligence-enabled platform, AOA's technology analyzes tumor marker gangliosides to facilitate the early detection of ovarian cancer. This approach not only helps healthcare providers implement more effective treatment strategies but also ensures that patients can access life-saving treatments sooner and at a more affordable cost.

SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.

Freedom Biosciences is a biotechnology company focused on developing next-generation psychedelic therapeutics. The company aims to create advanced psychedelic pharmaceuticals by harnessing the established pharmacology of compounds such as ketamine. Its mission is to provide innovative treatment options for medical professionals working with patients suffering from resistant depression and various mental disorders. Through its platform, Freedom Biosciences seeks to contribute to the evolving landscape of mental health treatment, addressing the needs of individuals who do not respond to conventional therapies.

PreComb is a biotechnology company focused on enhancing cancer therapy by developing innovative technologies that tailor treatments to individual patients, particularly for challenging cancers. The company specializes in automated microtumor-based profiling, which allows clinical institutions to conduct in vitro cancer diagnostics directly at the hospital. This technology enables the functional evaluation of various cancer drugs, combinations, and concentrations on patient-derived micro-tumors, thereby optimizing treatment outcomes. By improving the precision of cancer management, PreComb aims to increase success rates in therapies and ultimately enhance the quality of life for patients battling cancer.

Turn.bio is a biotechnology company focused on developing innovative therapies aimed at reversing aging and age-related diseases. Leveraging a patented mRNA platform technology known as ERA, along with a specialized delivery system called eTurna, the company targets the epigenome to restore optimal gene expression. By designing tailored therapies, Turn.bio addresses a range of conditions, including immune-related diseases such as cancer, dermatological issues, and ailments in ophthalmology, osteoarthritis, and the muscular system. The company's approach involves inducing the body to heal itself by instructing specific cells to combat disease and repair damaged tissue, thereby reprogramming cellular functions to enhance health and longevity.

HelixNano is a biotechnology startup that employs artificial intelligence and synthetic biology to develop innovative treatments for genetic diseases. Founded with backing from Y Combinator and venture capitalists, the company initially focused on creating cancer vaccines over two years. Currently, HelixNano is adapting its technology to combat COVID-19, aiming to produce precise and safe vaccine candidates. Its long-term goal is to develop a universal coronavirus vaccine that protects against future outbreaks.

First Longevity provides daily news and insights on the fast-growing longevity market. They offer antiaging, biotech, research, investment, supplements, and rejuvenation therapies. They offer news under diverse categories including AI, nanotechnology, drugs, agritech, and investment, along with monetizing its contents through display advertisements.

Deep Longevity, Inc. is a biotechnology company focused on developing innovative solutions for aging and longevity. Founded in 2016 and based in Hong Kong, the company specializes in creating aging and longevity clocks tailored for preventative medicine organizations, health clubs, insurance companies, and aging centers. Its offerings include Longevity Cloud, a platform that hosts deep aging clocks, and Young.AI, a web and mobile application designed to support longevity initiatives. Deep Longevity also develops multifactorial tools known as deep aging clocks to measure biological age, alongside a recommendation engine aimed at suggesting longevity interventions. The company employs advanced AI techniques to harness various data types, including clinical blood tests and other biological metrics, to enhance the accuracy of biological age predictions.